The SCN9A Polyclonal Antibody (PAC018875) is a crucial tool for researchers focusing on the SCN9A gene, which encodes the Nav1.7 sodium channel involved in pain perception and transmission. This antibody, produced in rabbits, exhibits high specificity and sensitivity towards human samples, making it ideal for Western blot applications. By targeting the SCN9A protein, researchers can effectively study its role in pain signaling pathways and explore its potential as a therapeutic target for pain management.
The SCN9A gene is known for its association with various pain disorders, including inherited erythromelalgia and paroxysmal extreme pain disorder. Understanding the function of the Nav1.7 sodium channel is essential for unraveling the mechanisms underlying these conditions and developing novel treatments. The use of the SCN9A Polyclonal Antibody enables researchers to delve deeper into the biology of pain perception and potentially discover new avenues for pain relief therapies.
Antibody Name:
SCN9A Antibody (PACO18875)
Antibody SKU:
PACO18875
Size:
50ul
Host Species:
Rabbit
Tested Applications:
ELISA, IHC
Recommended Dilutions:
ELISA:1:2000-1:5000, IHC:1:50-1:200
Species Reactivity:
Human
Immunogen:
Synthetic peptide of human SCN9A
Form:
Liquid
Storage Buffer:
-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Purification Method:
Antigen affinity purification
Clonality:
Polyclonal
Isotype:
IgG
Conjugate:
Non-conjugated
The image on the left is immunohistochemistry of paraffin-embedded Human brain tissue using PACO18875(SCN9A Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x200).
The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using PACO18875(SCN9A Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x200).
Background:
This gene encodes a voltage-gated sodium channel which plays a significant role in nociception signaling. Mutations in this gene have been associated with primary erythermalgia, channelopathy-associated insensitivity to pain, and paroxysmal extreme pain disorder.
